On July 6, Sinopharm Group rose 3.17% in regular trading, trading at HK$17.27/share, with turnover of HK$22.06 million.

On the news front, Sinopharm Group has recently signed a series of strategic cooperation agreements with leading innovative drug companies, reinforcing its competitive position in the innovative drug distribution sector. In late June, the company signed deep strategic partnership agreements with Innovent Biologics and Hengrui Medicine, upgrading collaboration to a full-chain, full-cycle ecosystem model. Earlier, it also partnered with East Sunshine Pharmaceutical to accelerate market coverage of innovative drugs. The agreements aim to integrate distribution resources with innovative product pipelines, enhancing drug accessibility nationwide.

Additionally, China CITIC Financial Asset Management increased its stake by 3.6624 million shares on June 26 at HK$15.86 per share, lifting its holding to 5.01%. This institutional inflow, combined with the strategic partnerships strengthening the company's distribution moat, collectively boosted market sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)